Current chemotherapy for advanced non-small-cell lung cancer (NSCLC) is as good as it can get so, according to one Italian oncologist, so clinicians need to turn their attention to choosing the ideal maintenance regimen for patients who respond well to first-line treatment. A review article culls the latest data on NSCLC maintenance therapy, exploring the pros and cons of several approaches to prolonging survival without upping toxicity.
RESULT: Maintenance therapy: a new treatment paradigm in advanced non-small-cell lung cancer
Current Opinion in Oncology | Mar 01, 2013 (FREE FULL TEXT)
Maintenance therapy with gefitinib(Drug information on gefitinib) (Iressa) boosted progression-free survival (PFS) compared with placebo in an Asia-based study of advanced NSCLC patients who achieved disease control after initial chemotherapy. But is PFS a solid enough outcome on which to base the benefits of maintenance therapy? The trialists say “yes,” but an expert commentary on the study offers some perspective on relying on PFS for making long-term treatment protocol decisions.
RESULT: Is benefit of maintenance therapy for NSCLC best defined by progression-free survival?
The Lancet Oncology | May 01, 2012 (FREE FULL TEXT with registration)
RESULT: Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial
The Lancet Oncology | May 01, 2012 (Free abstract. Full text $31.50)
URL
